STALICLA
STALICLA SA is a Swiss clinical-stage biopharmaceutical company developing precision-medicine approaches for neurodevelopmental and neuropsychiatric disorders. The company employs a multi-omics DEPI platform to identify patient subgroups and match them with targeted therapeutic candidates; its pipeline includes subgroup-matched programs such as STP1 for Autism Spectrum Disorder and STP7 for Substance Use Disorder, and it conducts clinical collaborations to advance these programs.
Leadership & Board
- Current Number of Employees
- 23
- Current LinkedIn Followers
- 5,880
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $3M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $3M
- Latest Funding Round
- Investment
- Post-Money Valuation
- ―
Employee Trend
STALICLA had 23 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
STALICLA had 5,880 followers as of October 12, 2026. The number of followers increased by 8 (0.14%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jul 30, 2025 | Investment | $2.50M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Addex Therapeutics | Investment |
Similar Companies
A snapshot of private companies similar to STALICLA, helping you discover and navigate related company profiles.
Related News and Analysis
